Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Hepatocellular Carcinoma|Hepatocellular Carcinoma Non-resectable|Liver Cancer
DEVICE: EYE90 Microspheres Treatment
Overall response rate (ORR), The percentage of subjects with ORR using local mRECIST, as assessed by independent panel review., 6 months|Duration of response (DoR), DoR is defined as response ≥ 6 months for ≥ 60% of responders first occurrence of CR or PR, 6 months|Incidence of adverse events (AEs), Incidence of AEs, grouped by System Organ Class (SOC) and Preferred Term (PT), relatedness to study treatment/procedure, and severity., 12 months|Incidence of serious adverse events (SAEs), Incidence of SAEs, grouped by SOC and PT, relatedness to study treatment/procedure, and severity., 12 months
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.